Extend your funding runway: How to maintain capital efficiency in an improving market
As we enter a new cycle of increased investment activity with rising IPOs and continued "mega-rounds," biotech companies face a critical challenge: How to maintain fiscal discipline when funding becomes more accessible. This webinar addresses the paradox many companies experienced during the 2020-2021 funding boom – raising capital but subsequently losing efficiency in deployment. We'll provide actionable approaches for maintaining strategic discipline even as market conditions improve, ensuring sustainable growth and avoiding the common pitfalls of resource misallocation during funding upswings
Learning objectives:
- Implement capital-efficient development strategies tailored to 2026's funding environment, including prioritization frameworks and potential geographic diversification
- Design streamlined development pathways that optimize the balance between accelerated development and prudent spending, maintaining focus on critical value inflection points
- Evaluate and pursue alternative operational models including strategic outsourcing, shared resource arrangements, and virtual team structures that minimize fixed costs while maximizing development capabilities
Related Insights
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
CTB Blog
Even when capital flows freely, biotechs benefit from efficiency
Mar 24, 2026
CTB Blog
5 ways to secure biotech funding in 2026
Mar 19, 2026
CTB Podcast
Bedside to Biotech: Building Trust, Storytelling in Science, and Pediatric Cancer Innovation
May 12, 2025
CTB Podcast
Pioneering oncology trials with AVEO Oncology
Mar 11, 2025
CTB Podcast
Introducing Clinical Trialblazers!
Mar 6, 2025
CTB Podcast
Biotech’s Next Era: Data, AI and the Future of Decision-Making with Jay Roberts
Aug 28, 2026
CTB Webinar
Rethinking Phase I: Five strategies for faster proof of concept
Aug 4, 2026
CTB Podcast
A Journey through Academia, Big Pharma and Biotech: Building Breakthrough Medicines with Dr. Briggs Morrison
Aug 3, 2026
Related Insights
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
CTB Blog
Even when capital flows freely, biotechs benefit from efficiency
Mar 24, 2026
CTB Blog
5 ways to secure biotech funding in 2026
Mar 19, 2026
CTB Podcast
Bedside to Biotech: Building Trust, Storytelling in Science, and Pediatric Cancer Innovation
May 12, 2025
CTB Podcast
Pioneering oncology trials with AVEO Oncology
Mar 11, 2025
CTB Podcast
Introducing Clinical Trialblazers!
Mar 6, 2025
CTB Podcast
Biotech’s Next Era: Data, AI and the Future of Decision-Making with Jay Roberts
Aug 28, 2026
CTB Webinar
Rethinking Phase I: Five strategies for faster proof of concept
Aug 4, 2026
CTB Podcast
A Journey through Academia, Big Pharma and Biotech: Building Breakthrough Medicines with Dr. Briggs Morrison
Aug 3, 2026